
---
title: '研究发现生物标志物或可有助于预测免疫疗法优势'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202108/26/212348cjwwwln02w2a2wb1.jpg'
author: 科学网
comments: false
date: Thu, 26 Aug 2021 21:31:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202108/26/212348cjwwwln02w2a2wb1.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;">研究确定了可能有助于预测免疫治疗益处的生物标志物</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202108/26/212348cjwwwln02w2a2wb1.jpg" title alt="20210330-covid.jpg" width="592" height="561" style="width: 592px; height: 561px;" referrerpolicy="no-referrer"><br></span></p><p style="line-height: 2em;"><a href="https://www.mskcc.org/immunotherapy-msk" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor</span></a><span style="font-size: 18px; font-family: "times new roman";">. Credit: NIAID</span><span style="font-family: "times new roman"; font-size: 18px;"> </span></p><p style="line-height: 2em; text-align: center;"><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank"><span style="font-family: "times new roman"; font-size: 18px;"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202108/26/213420sptqnudqoynnkkne.jpg" title alt="20210330-covid.jpg" referrerpolicy="no-referrer"></span></a><span style="font-family: "times new roman"; font-size: 18px;"><br></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">据美国纽约纪念斯隆·凯特琳癌症中心</span> (</span><a href="https://www.mskcc.org/" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">Memorial Sloan Kettering Cancer Center</span></a><span style="font-size: 18px; font-family: "times new roman";">)2021<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>25<span style="font-size: 18px; font-family: 宋体;">日提供的消息，该中心的研究人员与美国威尔康乃尔医学院（</span>Weill Cornell Medical College, New York<span style="font-size: 18px; font-family: 宋体;">）、帕克癌症免疫治疗研究所（</span>Parker Institute for Cancer Immunotherapy, San Francisco<span style="font-size: 18px; font-family: 宋体;">）、德克萨斯大学安德森癌症中心（</span>University of Texas, MD Anderson Cancer Center<span style="font-size: 18px; font-family: 宋体;">）、德克萨斯大学西南医学中心（</span>University of Texas Southwestern Medical Center<span style="font-size: 18px; font-family: 宋体;">）、斯隆</span>·<span style="font-size: 18px; font-family: 宋体;">凯特林研究所（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">Sloan Kettering Institute</a>, New York<span style="font-size: 18px; font-family: 宋体;">）的研究人员合作，研究确定了可能有助于预测免疫治疗益处的生物标志物（</span><a href="https://californianewstimes.com/study-identifies-biomarker-that-may-help-predict-benefits-of-immunotherapy/498968/" target="_blank">Study identifies biomarker that may help predict benefits of immunotherapy</a><span style="font-size: 18px; font-family: 宋体;">）。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">近年来，基于免疫的癌症治疗让医生和患者都燃起了希望。被称为免疫检查点抑制剂（</span>immune checkpoint inhibitors<span style="font-size: 18px; font-family: 宋体;">）的药物已经为越来越多的几种癌症患者提供了挽救生命的好处，包括黑色素瘤（</span>melanoma<span style="font-size: 18px; font-family: 宋体;">）、肺癌（</span>lung cancer<span style="font-size: 18px; font-family: 宋体;">）、膀胱癌（</span>bladder cancer<span style="font-size: 18px; font-family: 宋体;">）等。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">尽管这些药物令人兴奋，但令人沮丧的症结在于医生无法预测哪些人会受益，哪些人不会受益。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">2021<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>25<span style="font-size: 18px; font-family: 宋体;">日，纪念斯隆·凯特琳癌症中心的一组研究人员在《科学转化医学》（</span><a href="https://stm.sciencemag.org/content/13/608/eabf5107" target="_blank" style="box-sizing: border-box; background-color: rgb(255, 255, 255); cursor: pointer; color: rgb(9, 104, 195); text-decoration: underline; white-space: normal; font-family: "times new roman"; font-size: 18px;"><span style="font-family: "times new roman"; font-size: 18px;">Science Translational Medicine</span></a><span style="font-size: 18px; font-family: 宋体;">）杂志发表论文——</span>Ronglai Shen, Michael A. Postow, Matthew Adamow, Arshi Arora, Margaret Hannum, Colleen Maher, Phillip Wong, Michael A. Curran, Travis J. Hollmann, Liwei Jia, Hikmat Al-Ahmadie, Niamh Keegan, Samuel A. Funt, Gopa Iyer, Jonathan E. Rosenberg, Dean F. Bajorin, Paul B. Chapman, Alexander N. Shoushtari, Allison S. Betof, Parisa Momtaz, Taha Merghoub, Jedd D. Wolchok, Katherine S. Panageas, Margaret K. Callahan. </span><a href="https://stm.sciencemag.org/content/13/608/eabf5107" target="_self"><span style="font-size: 18px; font-family: "times new roman";">LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade</span></a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://medicalxpress.com/journals/science-translational-medicine/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Science Translational Medicine</span></a><span style="font-size: 18px; font-family: "times new roman";">, 25 Aug 2021; Vol. 13, Issue 608, eabf5107. </span><a href="http://dx.doi.org/10.1126/scitranslmed.abf5107" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.1126/scitranslmed.abf5107</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">此文报告称，血液中免疫细胞（</span><a href="https://medicalxpress.com/tags/immune+cells/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">immune cells</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）上的标记物的特定模式或“特征”可能是检查点免疫治疗反应的生物标志物（</span>biomarker<span style="font-size: 18px; font-family: 宋体;">）。在这种免疫特征中，一种分子</span>LAG-3<span style="font-size: 18px; font-family: 宋体;">提供了识别患者预后较差的关键信息。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这一关联在一组转移性黑色素瘤（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">metastatic melanoma</a><span style="font-size: 18px; font-family: 宋体;">）患者中被发现，并在第二组转移性膀胱癌（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">metastatic bladder cancer</a><span style="font-size: 18px; font-family: 宋体;">）患者中得到验证，表明这一潜在的生物标志物可能广泛适用于各种癌症患者。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">据纪念斯隆·凯特琳癌症中心</span> (</span><a href="https://www.mskcc.org/" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">Memorial Sloan Kettering, </span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">简称</span>MSK)<span style="font-size: 18px; font-family: 宋体;">帕克癌症免疫治疗研究所（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">Parker Institute for Cancer Immunotherapy</a><span style="font-size: 18px; font-family: 宋体;">）研究员、领导此项研究的医师兼研究员玛格丽特·卡拉汉</span>(Margaret Callahan)<span style="font-size: 18px; font-family: 宋体;">说，这项研究大量的患者队列、强有力的临床随访以及采用了严格的统计方法，这让她“对免疫信号告诉我们哪些人对免疫治疗有反应以及为什么有反应这一重要信息充满热情。”</span></span><span style="font-family: "times new roman"; font-size: 18px;">这些发现为前瞻性临床试验铺平了道路，这些临床试验旨在测试将这种生物标志物纳入患者护理是否能改善那些不太可能从现有疗法中获益的患者的预后。</span></p><p style="line-height: 2em;"><strong><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">大数据，大结论（</span><a href="https://californianewstimes.com/study-identifies-biomarker-that-may-help-predict-benefits-of-immunotherapy/498968/" target="_blank">Big data, big conclusion</a><span style="font-size: 18px; font-family: 宋体;">）</span></span></strong></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在他们的发现中，研究人员有数据支持他们。作为世界上最早开始用免疫疗法治疗大量患者的癌症中心之一，</span>MSK<span style="font-size: 18px; font-family: 宋体;">拥有一个储存多年来治疗的数百名患者的血液的仓库，由</span>MSK<span style="font-size: 18px; font-family: 宋体;">研究人员</span>Jedd Wolchok<span style="font-size: 18px; font-family: 宋体;">和</span>Phil Wong(<span style="font-size: 18px; font-family: 宋体;">该研究的共同作者</span>)<span style="font-size: 18px; font-family: 宋体;">率先开展的工作。该研究的研究人员利用从</span>2011~2017<span style="font-size: 18px; font-family: 宋体;">年在</span>MSK<span style="font-size: 18px; font-family: 宋体;">进行的</span>7<span style="font-size: 18px; font-family: 宋体;">项不同临床试验中收集的患者预处理前的血液样本得出了他们的发现。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">为了挖掘血液中的线索，研究人员使用了一种叫做流式细胞术（</span>flow cytometry<span style="font-size: 18px; font-family: 宋体;">）的技术。流式细胞术是一种当单个细胞流过激光时快速分析其属性的工具。研究人员的目标是识别患者免疫细胞上发现的标志物，这些标志物与患者对纳武单抗</span>(nivolumab<span style="font-size: 18px; font-family: 宋体;">或</span>Opdivo)<span style="font-size: 18px; font-family: 宋体;">和派姆单抗</span>(pembrolizumab<span style="font-size: 18px; font-family: 宋体;">或</span>Keytruda)<span style="font-size: 18px; font-family: 宋体;">等</span>PD-1<span style="font-size: 18px; font-family: 宋体;">靶向药物的免疫治疗反应相关。但这并不是一项入普通人眼的工作。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">MSK<span style="font-size: 18px; font-family: 宋体;">流行病学和生物统计学部门（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">Department of Epidemiology and Biostatistics at MSK</a><span style="font-size: 18px; font-family: 宋体;">）的统计学家，也是开发了此研究中使用的一些统计工具的研发者沈荣来（</span>Ronglai Shen<span style="font-size: 18px; font-family: 宋体;">音译）说：“当你想到一个病人的血液样本中有成千上万的血细胞，而我们正在绘制出近</span>100<span style="font-size: 18px; font-family: 宋体;">种不同的免疫细胞亚群的组成，这是一个真正的挑战，要有效地提取临床相关信息。这就是我们作为数据科学家能够在研究中帮助玛格丽特·卡拉汉博士和其他医学研究人员的地方。这是技术的完美结合。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">沈荣来博士和其他数据科学家凯瑟琳·帕尼亚吉斯</span>(Katherine Panageas)<span style="font-size: 18px; font-family: 宋体;">开发的统计工具使研究小组能够根据血液标记物的独特模式，将患者分成三种典型的免疫特征或免疫类型。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">跳出来的免疫型（</span>immunotype<span style="font-size: 18px; font-family: 宋体;">）是一组患者，他们在各种</span>T<span style="font-size: 18px; font-family: 宋体;">细胞亚群上表达了高水平的</span>LAG-3<span style="font-size: 18px; font-family: 宋体;">蛋白。研究小组发现，与具有</span>LAG<sup>-</sup><span style="font-size: 18px; font-family: 宋体;">免疫型（</span>LAG<sup>- </sup>immunotype<span style="font-size: 18px; font-family: 宋体;">）的患者相比，具有这种免疫型的患者的生存时间要短得多</span>:<span style="font-size: 18px; font-family: 宋体;">对于黑色素瘤患者，中位生存时间超过</span>4<span style="font-size: 18px; font-family: 宋体;">年</span>(22.2<span style="font-size: 18px; font-family: 宋体;">个月</span>vs 75.8<span style="font-size: 18px; font-family: 宋体;">个月</span>)<span style="font-size: 18px; font-family: 宋体;">，此差异具有统计学意义。</span></span></p><p style="line-height: 2em;"><strong><span style="font-size: 18px; font-family: 宋体;">以</span><span style="font-family: "times new roman"; font-size: 18px;">LAG-3</span><span style="font-size: 18px; font-family: 宋体;">为目标（</span><a href="https://californianewstimes.com/study-identifies-biomarker-that-may-help-predict-benefits-of-immunotherapy/498968/" target="_blank"><span style="font-family: "times new roman"; font-size: 18px;">LAG-3 as a target</span></a><span style="font-size: 18px; font-family: 宋体;">）</span></strong><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">LAG-3<span style="font-size: 18px; font-family: 宋体;">是淋巴细胞激活基因</span>3<span style="font-size: 18px; font-family: 宋体;">（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">short for lymphocyte-activation gene 3</a><span style="font-size: 18px; font-family: 宋体;">），它属于免疫检查点分子家族。就像更广为人知的细胞毒</span>T<span style="font-size: 18px; font-family: 宋体;">淋巴细胞相关抗原</span>4(Cytotoxic T - Lymphocyte Antigen 4<span style="font-size: 18px; font-family: 宋体;">简称</span>CTLA-4)<span style="font-size: 18px; font-family: 宋体;">和</span>PD-1<span style="font-size: 18px; font-family: 宋体;">检查点一样，</span>LAG-3<span style="font-size: 18px; font-family: 宋体;">对免疫反应有抑制作用，也就是说它会抑制免疫反应。目前，一些针对</span>LAG-3<span style="font-size: 18px; font-family: 宋体;">的药物正在临床开发中，尽管确定谁可能从这些药物中受益最大一直是一个挑战。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">当玛格丽特·卡拉汉博士和她的同事开始这项研究时，他们并没有打算专门关注</span>LAG-3<span style="font-size: 18px; font-family: 宋体;">。她说</span>:<span style="font-size: 18px; font-family: 宋体;">“我们让数据引领我们，而</span>LAG-3<span style="font-size: 18px; font-family: 宋体;">是被颠覆的。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这项研究的一个优点是它同时使用了“发现集</span>(discovery set)<span style="font-size: 18px; font-family: 宋体;">”和“验证集</span>(validation set)<span style="font-size: 18px; font-family: 宋体;">”。这意味着，研究人员对来自一大群患者的一组血液样本进行了初步分析。在本例中，有</span>188<span style="font-size: 18px; font-family: 宋体;">名黑色素瘤患者。然后，他们要问及他们在发现集中确定的免疫特征，是否可以预测完全不同的一批患者及</span>94<span style="font-size: 18px; font-family: 宋体;">名膀胱癌患者的结果。答案是：有可能，而且很好。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">玛格丽特·卡拉汉博士说</span>:<span style="font-size: 18px; font-family: 宋体;">“当我们观察接受检查点阻断的膀胱癌患者的验证队列时，那些具有</span>LAG<sup>+</sup><span style="font-size: 18px; font-family: 宋体;">免疫型（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">LAG<sup>+</sup> immunotype</a><span style="font-size: 18px; font-family: 宋体;">）的患者的应答率为</span>0%<span style="font-size: 18px; font-family: 宋体;">。零。没有一个人回应。相比之下，具有</span>LAG<sup>-</sup><span style="font-size: 18px; font-family: 宋体;">免疫型（</span><a href="https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy" target="_blank">LAG<sup>-</sup> immunotype</a><span style="font-size: 18px; font-family: 宋体;">）的患者的应答率为</span>49%<span style="font-size: 18px; font-family: 宋体;">。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">由于大量的数据集，科学家们也能够询问他们的</span>LAG<sup>+</sup><span style="font-size: 18px; font-family: 宋体;">免疫型与其他已知的反应生物标志物，特别是</span>PD-L1<span style="font-size: 18px; font-family: 宋体;">状态和肿瘤突变负担（</span>tumor mutation burden<span style="font-size: 18px; font-family: 宋体;">）相比如何。他们发现，免疫类型提供了关于患者预后的新的独立信息，而不仅仅是与其他生物标志物相呼应。</span></span></p><p style="line-height: 2em;"><strong><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">为什么需要好的生物标记？（</span><a href="https://californianewstimes.com/study-identifies-biomarker-that-may-help-predict-benefits-of-immunotherapy/498968/" target="_blank">Why good biomarkers are needed？</a><span style="font-size: 18px; font-family: 宋体;">）</span></span></strong></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">生物标记在癌症中很重要有几个原因。它们可以帮助临床医生和患者选择最佳的治疗方法，并可能使他们避免不必要的治疗或不太可能起作用的治疗。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">凯瑟琳·帕尼亚吉斯博士说：“免疫治疗药物并非没有潜在的毒性。所以，如果我们知道患者不太可能有反应，就能避免他们接受治疗的潜在风险，这是一个很大的进步。”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">第二个原因是成本。免疫治疗药物价格昂贵，因此有办法更好地为患者匹配现有药物是至关重要的。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">而且，由于研究人员使用患者的血液样本确定了这种生物标志物，因此，通过简单的抽血，就可以对患者的这种标志物进行评估，这带来了令人愉快的前景。目前使用的其他生物标记物依赖于通常通过活检获得的肿瘤组织。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">玛格丽特·卡拉汉博士说</span>:<span style="font-size: 18px; font-family: 宋体;">“如果我告诉你，你可以做一次简单的抽血，然后在几天内就能知道你要接受什么样的治疗，我会说，没什么比这更好的了。当然，在这些研究成果应用于临床病人之前，还有很多工作要做，但我们对应用这些发现的潜力非常感兴趣。”</span></span></p><p style="line-height: 2em;"><strong><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">未来研究什么呢？（</span><a href="https://californianewstimes.com/study-identifies-biomarker-that-may-help-predict-benefits-of-immunotherapy/498968/" target="_blank">What's next?</a><span style="font-size: 18px; font-family: 宋体;">）</span></span></strong></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">这项研究的一个局限性是它是回顾性的，这意味着分析的数据来自多年前收集的并保存在冰箱中的血液样本。为了证实这些发现有可能使患者受益，研究人员将需要在前瞻性研究中检验他们的假设，这意味着患者被纳入一项专门设计的临床试验，以测试在治疗决定中使用这种免疫类型可以改善患者结果的想法。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">玛格丽特·卡拉汉博士说：“我最兴奋的是前瞻性评估，这样我们不仅可以识别那些用传统疗法治疗不好的病人，我们还可以给这些病人提供其他可能帮助他们的治疗方案，基于我们的知识</span>LAG-3<span style="font-size: 18px; font-family: 宋体;">究竟在生物上能做什么</span>,<span style="font-size: 18px; font-family: 宋体;">有待研究。”上述介绍，仅供参考。欲了解更多信息，敬请注意浏览<a href="https://stm.sciencemag.org/content/13/608/eabf5107" target="_self">原文</a>或者<a href="https://californianewstimes.com/study-identifies-biomarker-that-may-help-predict-benefits-of-immunotherapy/498968/" target="_blank">相关报道</a>。</span></span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2021-07-scoring-neck-cancer-patient-response.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Scoring system predicts head and neck cancer patient response to immunotherapy</span></a></p><p style="line-height: 2em;"><a href="https://stm.sciencemag.org/content/13/608/eabf5107" target="_self"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Pinpointing checkpoint response</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Immune checkpoint inhibitors can aid the immune system of some to effectively attack tumors, but identifying those patients for whom they will be effective is still a challenge. Aroraet al. investigated the abundances of different types of immune cells in the peripheral blood of patients with cancer who had better or worse outcomes after immunotherapy treatment. They found that a LAG-3<sup>+</sup>CD8<sup>+</sup> T cell population correlated with poorer outcome after immune checkpoint blockade treatment in a cohort of patients with melanoma and in an independent cohort treated for urothelial carcinoma, suggesting a potential way to identify patients who will respond to checkpoint inhibitors.</span></p><p style="line-height: 2em;"><a href="https://stm.sciencemag.org/content/13/608/eabf5107" target="_self"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Abs<span style="font-size: 18px;">tract</span></span></a></p><p style="margin: 2px 0px 0px; background: rgb(230, 230, 230); line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; color: #333333;">Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however, they benefit only a subset of patients and biomarkers to guide immune checkpoint blockade (ICB) treatment choices are lacking. We designed this study to identify blood-based correlates of clinical outcome in ICB-treated patients. We performed immune profiling of 188 ICB-treated patients with melanoma using multiparametric flow cytometry to characterize immune cells in pretreatment peripheral blood. A supervised statistical learning approach was applied to a discovery cohort to classify phenotypes and determine their association with survival and treatment response. We identified three distinct immune phenotypes (immunotypes), defined in part by the presence of a LAG-3</span><sup><span style="font-size: 18px; color: #333333;">+</span></sup><span style="font-size: 18px; color: #333333;">CD8</span><sup><span style="font-size: 18px; color: #333333;">+</span></sup><span style="font-size: 18px; color: #333333;"> T cell population. Patients with melanoma with a LAG</span><sup><span style="font-size: 18px; color: #333333;">+ </span></sup><span style="font-size: 18px; color: #333333;">immunotype had poorer outcomes after ICB with a median survival of 22.2 months compared to 75.8 months for those with the LAG</span><sup><span style="font-size: 18px; color: #333333;">−</span></sup><span style="font-size: 18px; color: #333333;"> immunotype (<em>P</em> = 0.031). An independent cohort of 94 ICB-treated patients with urothelial carcinoma was used for validation where LAG</span><sup><span style="font-size: 18px; color: #333333;">+</span></sup><span style="font-size: 18px; color: #333333;">immunotype was significantly associated with response (<em>P</em> = 0.007), survival (<em>P</em> < 0.001), and progression-free survival (<em>P</em> = 0.004). Multivariate Cox regression and stratified analyses further showed that the LAG</span><sup><span style="font-size: 18px; color: #333333;">+</span></sup><span style="font-size: 18px; color: #333333;"> immunotype was an independent marker of outcome when compared to known clinical prognostic markers and previously described markers for the clinical activity of ICB, PD-L1, and tumor mutation burden. The pretreatment peripheral blood LAG</span><sup><span style="font-size: 18px; color: #333333;">+</span></sup><span style="font-size: 18px; color: #333333;"> immunotype detects patients who are less likely to benefit from ICB and suggests a strategy for identifying actionable immune targets for further investigation.</span></span></p><p><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1301567.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1301567.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1301492.html" target="_black">一名学生的使命:保护世界上最珍贵的资源</a><br>                    <!--大赛结束-->
                                        
  
</div>
            